Literature DB >> 11591024

[IFN-alpha consolidation after intensive chemotherapy does not bring any survival advantage in low-grade non-Hodgkin lymphoma].

M Klee, H J Illiger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11591024     DOI： 10.1007/bf03353387

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.

Authors:  R V Smalley; J W Andersen; M J Hawkins; V Bhide; M J O'Connell; M M Oken; E C Borden
Journal:  N Engl J Med       Date:  1992-11-05       Impact factor: 91.245

2.  Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Solal-Celigny; E Lepage; N Brousse; F Reyes; C Haioun; M Leporrier; M Peuchmaur; A Bosly; Y Parlier; P Brice
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

3.  Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.

Authors:  R I Fisher; B W Dana; M LeBlanc; C Kjeldsberg; J D Forman; J M Unger; S P Balcerzak; E R Gaynor; V Roy; T Miller
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

4.  Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.

Authors:  A Aviles; G Duque; A Talavera; R Guzman
Journal:  Leuk Lymphoma       Date:  1996-02

5.  Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

Authors:  P Solal-Céligny; E Lepage; N Brousse; C L Tendler; P Brice; C Haïoun; J Gabarre; B Pignon; G Tertian; R Bouabdallah; J F Rossi; C Doyen; B Coiffier
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.